Bristol Myers Squibb Co.’s Orencia on Wednesday became the first drug to win U.S. approval for the prevention of acute Graft versus Host Disease (aGvHD), a potentially fatal complication that could occur after a stem cell transplant. The Food and Drug Administration (FDA) has cleared the drug in combination with certain immunosuppressants for use in…